Phase I Clinical and Pharmacokinetic Study of LU103793 (Cemadotin Hydrochloride) as an Intravenous Bolus Injection in Patients with Metastatic Solid Tumors

Oncology Research and Treatment

Volumn 19, Issue 6, 1996, Pages 490-495

  Mross, K ^a,b   Herbst, K ^a   Berdel, W E ^c   Korfel, A ^c   Von Broen, I M ^d   Bankmann, Y ^e  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Klinik für Internistische Onkologie   (Switzerland)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Abteilung Onkologie/Immunologie   (Germany)

^e Knoll AG   (Germany)

Author keywords

Anti cancer agent; Malignant Tumors; Pharmacokinetics; Phase I study; Toxicity

Indexed keywords

CEMADOTIN; CYTOTOXIC AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; PHASE 1 CLINICAL TRIAL; SOLID TUMOR; VOMITING;

EID: 0030483184     PISSN: 22965270     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218861     Document Type: Article

References (14)

1. Pettit GR, Kamano Y, Fujii Y, Harald CL, Inone M, Brown P, Gust D, Kitahara K, Schmidt JM: Marine animal biosynthetic constituents for cancer chemotherapy, J Nat Prod 1981:44:482-485.
2. Pettit GR, Kamano Y, Herald CL, Tuinman A A, Boettner FE, Kizu H, Schmidt JM, Baczynskyi L, Tomec KB, Bontems RJ: Hie isolation and structure of a remarkable marine antineoplastic constituent: Dolastin 10. J Am Chem Soc 1987:109:6883-6885.
3. Pettit GR, Kamano Y, Dufresnc C, Cerny RL, Herald CL, Schmidt JM: Isolation and structure of the cytostatic linear depsipeptide dolastin 15. J Org Chem 1989;54:6005-6006.
4. Quentmeier H, Brauner S, Petitt GR, Drexler HG: Cytostatic effects of dolastin 10 and dolastin 15 on human leukemia cell lines, Leuk Lymphoma 1992; 6:245-250.
5. Hu ZB, Gignac SM, Quentmeier H, Petitt GR, Drexler HG: Effects of dolastins on human B-lympho-cytic leukemia cell lines, Leukemia Res 1993:4: 333-339.
6. Hoff DD von: Results of LU103793 within the human colony forming assay, Investigators broschure LU103793. March 1995.
7. Bai R, Pettit GR, Hamel E: Dolastin 10. a powerful cytostatic peptide derived from a marine animal, Inhibition of tubulin plymerization mediated through the vinca alkaloid binding domain, Biochem Pharmacol 1990:39:2637-2645.
8. Bai R, Friedman SJ, Pettit GR, Hamel E: Dolastin 15. a potent antimitotic depsipeptide derived from Dola-bella Auricularia, Interaction with tubulin and effects on cellular microtublcs, Biochem Pharmacol 1992: 43:2637-2645.
9. Gibaldi M: Biopharmaceutics and Clinical Pharmacokinetics, Philadelphia, Lea and Febiger, 1991.
10. Heinzel G, Wolozczak R, Thomann P: Pharmacokinetic and Pharmacodynamic Data System for the PC, Stuttgart, Fischer, 1993.
11. Villalona-Calero M, Degen D, Barlozzari T, Von Hoff D: LU 103793: Evaluation by human tumor clonogenic assay of a novel dolastin, AACR Proc 1995;abstract no, 2349.
12. Villalona-Calero M, Jakimowicz K, Razvillas B, Rinaldi G, Eckhardt C, Aylesworth C, Fischkoff S, Von Hoff D: LU 103793: A phase I study of a novel dolastin, Ann Oncol 1996:7(suppl 1):100.
13. Mross K, Herbst K, Berdel W, von Broen IM, Hoss-feld DK: Phase I study with a cytotoxic peptide LUT03793 administered as iv bolus injection, Ann Oncol 1996;7(suppl 1):100.
14. Mross K, Ficbig HH, Berdel VV, Bankmann Y, von Broen IM, Unger C: Clinical and pharmacokinetic phase I study with LU 103793 administered as 24-hour infusion, Proc ASCO 1996:15:482.